Glioma stem cells and immunotherapy for the treatment of malignant gliomas
- PMID: 23762610
- PMCID: PMC3671309
- DOI: 10.1155/2013/673793
Glioma stem cells and immunotherapy for the treatment of malignant gliomas
Abstract
Stem cell research has led to the discovery of glioma stem cells (GSCs), and because these cells are resistant to chemotherapy and radiotherapy, analysis of their properties has been rapidly pursued for targeted treatment of malignant glioma. Recent studies have also revealed complex crosstalk between GSCs and their specialized environment (niche). Therefore, targeting not only GSCs but also their niche may be a principle for novel therapies of malignant glioma. One possible novel strategy for targeting GSCs and their niches is immunotherapy with different antitumor mechanism(s) from those of conventional therapy. Recent clinical studies of immunotherapy using peptide vaccines and antibodies have shown promising results. This review describes the recent findings related to GSCs and their niches, as well as immunotherapies for glioma, followed by discussion of immunotherapies that target GSCs for the treatment of malignant glioma.
References
-
- Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. Journal of Neuropathology and Experimental Neurology. 2002;61(3):215–229. - PubMed
-
- Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine. 1997;3(7):730–737. - PubMed
-
- Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Research. 2003;63(18):5821–5828. - PubMed
-
- Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391–403. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
